Board of Directors
Mr. Jim Mellon (Non-Executive Chairman)
Jim Mellon is an investor with interests in several industries. After leaving Oxford , where he studied PPE, he worked in Asia and the United States in two fund management companies, GT and Thornton, before establishing his own business in 1991. This now has two components – a listed fund management company – Charlemagne Capital – and an Asian mining group, Regent Pacific. In addition, Jim is the controlling shareholder and a director of Manx Financial Corporation , an Isle of Man based bank, Speymill Group, a property business, and Webis Holdings. He is a co-founder of Uramin and Red Dragon Resources, both mining groups. Burnbrae, his private company, is a substantial landlord in Germany and in the Isle of Man, and also owns outright the hotel chain Sleepwell Hotels. Jim spends most of his time working on startup ideas and on investing. His book, ‘Wake Up!’ was published in 2005 and the second book “10 Investments for the Ten Years Ahead “ in 2008 ” . Jim lives in the Isle of Man, Brussels and Ibiza. Jim is an honorary fellow of Oriel College, Oxford.
Mr Ronald Openshaw (Chief Executive Officer and Chief Financial Officer)
Ronald Openshaw has worked in the life sciences and healthcare sectors both in executive management and in an advisory role. He is the founder of the M&A and strategic consulting firm Lucia Capital LLP and previously he was an investment banker at Panmure Gordon & Co. Limited (latterly WestLB Panmure Limited) and then, most recently, Jefferies International Limited. He also served as CFO and acting CEO at Pharmagene plc until its merger with Asterand plc in 2006. Although not on the Board Ronald has advised the Board acting as Interim CFO at Plethora since February 2009 and he will continue in this role. Ronald Openshaw is Chair of the Nomination Committee.
Dr. Michael Wyllie (Chief Scientific Officer)
Mike Wyllie is a co-founder of Plethora. He has over 25 years of experience in senior management level positions within the pharmaceutical industry with American Home Products and Pfizer. He has considerable hands-on experience in all aspects of the drug discovery and development process and has been involved with new project inception, drug discovery and safety testing, early and late stage clinical development, regulatory filing and the successful commercialisation of products including Cardura® (doxazosin) and Viagra® (sildenafil). Dr. Wyllie sits on The Clinical Trial Design and Future Therapies in BPH Committees of the World Health Organisation International Consultations on Urological Disease and he is an assistant editor of the British Journal of Urology in the Sexual Medicine Section. He has over 100 publications and is named as the inventor of over 80 patents.
Dr Greg Bailey (Non-Executive Director)
Dr Bailey is an investor and entrepreneur in the biomedical sector having spent time previously as an investment banker and a physician. He is currently a Co-Chairman of Topix Pharma, Inc. and Chairman of Portage Biotech , Inc. He is the managing partner of Palantir Group, Inc., a biotech merchant bank. Dr Bailey has arranged and participated in multiple financings, M&A transactions, and taken a number of companies public. He personally co-founded or funded three companies currently valued at over 5 billion dollars including Medivation, Inc., the recently acquired Ascent Healthcare Solutions and VirnetX Inc. He has been a board member of several public companies. Dr. Bailey practiced emergency medicine for 10 years.
Mr. Mike Collis (Non-Executive Director)
Mike Collis is an advisor to Maven Capital Partners LLP (“Maven”), which manages the Capital for Enterprise Fund (“CfE”). CfE provided a £1m facility to the Company under which it has the right to appoint a director to the board. Mr Collis is a specialist in financial turnarounds and is a member of the Institute for Turnaround and also a Chartered Accountant. He is managing director of Arc Portfolio Management Limited. He was previously Head of Portfolio Management at Aberdeen Asset Managers Private Equity. He has served on the boards of a number of private companies often as a nominee of the investor. Mr Collis qualified as a Chartered Accountant with Arthur Andersen.